Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases.

Academic Article


  • OBJECTIVE: The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases. METHODS: Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression. RESULTS: Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years. CONCLUSION: HZ vaccination was significantly protective only for about 5 years among patients with AI.
  • Published In


  • AUTOIMMUNE DISEASES, HERPES ZOSTER, INFECTION, VACCINATION, Aged, Aged, 80 and over, Autoimmune Diseases, Female, Herpes Zoster, Herpes Zoster Vaccine, Humans, Incidence, Inflammation, Male, Medicare, Retrospective Studies, Treatment Outcome, United States, Vaccination
  • Digital Object Identifier (doi)

    Author List

  • Yun H; Xie F; Baddley JW; Winthrop K; Saag KG; Curtis JR
  • Start Page

  • 1083
  • End Page

  • 1087
  • Volume

  • 44
  • Issue

  • 7